Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quinine as a marker for aspiration in intubated patients
NCT02598713Phase 1Withdrawn
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2015
- Primary completion
- Jun 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of quinine in pulmonary aspiration and ventilator-associated pneumonia (VAP), sponsored by Massachusetts General Hospital. Primary endpoint: Oropharyngeal aspiration at 25 hours. Planned start Dec 2015; status: withdrawn.
02
Drugs
quinine
03
Conditions
pulmonary aspirationventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT02598713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598713.